Concentric Capital Strategies, LP

Concentric Capital Strategies, LP is a New York-based hedge fund specializing in healthcare and life sciences investing with a growth-oriented approach. The firm was founded by Russell Kamerman, who serves as Chief Investment Officer and brings deep expertise in healthcare sector analysis to the investment process. Filing with the SEC under CIK #0001851869, Concentric Capital Strategies represents a relatively newer entrant to the institutional investment landscape, with 13F filings reflecting its specialized investment mandate. Operating from New York's financial center, Concentric Capital Strategies benefits from proximity to major healthcare companies, biotechnology clusters, pharmaceutical headquarters, and the institutional investor community focused on life sciences. The firm's specialized focus positions it within a niche of healthcare-dedicated hedge funds that leverage deep sector expertise to identify investment opportunities across the pharmaceutical, biotechnology, medical device, and healthcare services subsectors. The firm's name—Concentric—suggests an investment philosophy built around focused, layered analysis radiating from core competencies in healthcare and life sciences. Under Kamerman's leadership, Concentric Capital Strategies applies specialized knowledge of drug development pipelines, regulatory pathways, competitive dynamics, and clinical trial interpretation to construct portfolios designed to capture value creation in the healthcare innovation ecosystem. Through the platform's 13F History tools, researchers can examine how the firm has positioned capital across healthcare subsectors.

Concentric Capital Strategies employs a growth-oriented, sector-specialist investment approach with concentrated expertise in healthcare and life sciences equities. The firm's strategy leverages deep fundamental research into pharmaceutical development, biotechnology innovation, and healthcare services transformation to identify companies positioned for above-market growth and value creation. The investment process centers on rigorous scientific and commercial analysis of healthcare companies. In biotechnology and pharmaceuticals, this includes assessment of drug pipelines, clinical trial data interpretation, regulatory approval probabilities, and competitive positioning within therapeutic categories. For healthcare services and medical technology companies, analysis extends to reimbursement dynamics, market share trends, and operational execution capabilities. Russell Kamerman's background provides the foundation for this specialized approach, enabling the investment team to evaluate complex scientific developments and translate clinical data into investment implications. The 13F Portfolio Composition reveals concentrated healthcare exposure, with positions spanning large-cap pharmaceutical companies, emerging biotechnology firms, and healthcare services providers. Top 10 Holdings Concentration typically reflects the conviction-driven nature of specialist healthcare investing. Selective technology exposure complements the core healthcare mandate, potentially including healthcare IT, diagnostic platforms, or technology companies enabling healthcare innovation. Sector Allocation History through the platform enables researchers to observe how Concentric Capital Strategies balances exposure across biotechnology, pharmaceuticals, medical devices, and healthcare services subsectors. The Moderate turnover profile suggests active management around clinical catalysts and pipeline developments while maintaining core positions in highest-conviction holdings.

Concentric Capital Strategies, LP presents a clearly defined profile as a specialized healthcare and life sciences hedge fund led by founder Russell Kamerman. The New York-based firm's sector expertise, growth-oriented mandate, and concentrated portfolio construction establish a coherent institutional identity for allocators seeking dedicated healthcare exposure with active management. Key observable characteristics from 13F filings include healthcare sector concentration, growth-oriented security selection, and active positioning around clinical and regulatory catalysts. The Historical Track Record reconstructed through backtesting services provides insight into compounding behavior, while Sharpe Ratio analysis quantifies risk-adjusted outcomes relative to the volatility inherent in biotechnology and pharmaceutical investing. For researchers analyzing Concentric Capital Strategies, the central diagnostic question involves regime sensitivity: How does the portfolio's concentrated healthcare exposure perform across different sector environments—including periods of biotech enthusiasm versus skepticism, varying interest rate regimes, and shifting political sentiment toward pharmaceutical pricing—and does the specialized expertise translate into consistent alpha generation within the healthcare sector?

Concentric Capital Strategies' risk characteristics reflect the inherent volatility of concentrated healthcare and biotechnology investing. The life sciences sector presents unique risk factors including binary clinical trial outcomes, regulatory approval uncertainties, patent cliff dynamics, and political sensitivity around drug pricing—all contributing to elevated Volatility Profile metrics compared to diversified equity strategies. Biotechnology investments, in particular, exhibit event-driven volatility around clinical data readouts, FDA advisory committee meetings, and regulatory decisions. Individual positions can experience dramatic single-day price movements based on clinical trial success or failure, creating potential for both substantial gains and significant drawdowns at the position level. The concentrated nature of specialist healthcare portfolios amplifies these dynamics at the total portfolio level. Max Drawdown Depth analysis through the platform's Portfolio Simulator provides essential context for understanding capital trajectory during challenging periods. Healthcare-focused strategies may experience drawdowns during sector-wide selloffs—such as those triggered by drug pricing political rhetoric or broader biotechnology sentiment shifts—even when underlying portfolio companies maintain fundamental progress. The Downside Capture Ratio relative to healthcare benchmarks offers insight into how effectively Concentric Capital Strategies manages sector-specific risk. Skilled healthcare investors may demonstrate differentiated downside characteristics through position sizing discipline around binary events, portfolio diversification across therapeutic categories, and hedging strategies that 13F disclosures may not fully capture. The firm's relatively recent establishment means that its 13F history spans fewer market cycles than longer-tenured managers, providing limited longitudinal data for assessing performance across dramatically different healthcare sector environments.